Abstract
Certain bacteria selectively attack tumor tissues and trigger tumor shrinkage by producing toxins and modulating the local immune system, but their clinical utility is limited because of the dangers posed by systemic infection. Genetic engineering can be used to minimize the risks associated with tumor-targeting pathogens, as well as to increase their efficiency in killing tumor cells. Advances in genetic circuit design have led to the development of bacterial strains with enhanced tumor-targeting capacities and the ability to secrete therapeutics, cytotoxic proteins and prodrug-cleaving enzymes, which allows their safe and effective use for cancer treatment. The present review details the recent advances in the design and application of these modified bacterial strains.
Keywords: Synthetic biology, cancer therapy, live vaccines, prodrug cleavage, Salmonella, Clostridium, Bifidobacterium.
Current Pharmaceutical Design
Title:Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Volume: 22 Issue: 11
Author(s): Ebuzer Kalyoncu, Tolga T. Olmez, Alper D. Ozkan and Omer F. Sarioglu
Affiliation:
Keywords: Synthetic biology, cancer therapy, live vaccines, prodrug cleavage, Salmonella, Clostridium, Bifidobacterium.
Abstract: Certain bacteria selectively attack tumor tissues and trigger tumor shrinkage by producing toxins and modulating the local immune system, but their clinical utility is limited because of the dangers posed by systemic infection. Genetic engineering can be used to minimize the risks associated with tumor-targeting pathogens, as well as to increase their efficiency in killing tumor cells. Advances in genetic circuit design have led to the development of bacterial strains with enhanced tumor-targeting capacities and the ability to secrete therapeutics, cytotoxic proteins and prodrug-cleaving enzymes, which allows their safe and effective use for cancer treatment. The present review details the recent advances in the design and application of these modified bacterial strains.
Export Options
About this article
Cite this article as:
Kalyoncu Ebuzer, Olmez T. Tolga, Ozkan D. Alper and Sarioglu F. Omer, Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities, Current Pharmaceutical Design 2016; 22 (11) . https://dx.doi.org/10.2174/1381612822666151210123752
DOI https://dx.doi.org/10.2174/1381612822666151210123752 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Ecto-Nucleotidase Inhibitors: Recent Developments in Drug Discovery
Mini-Reviews in Medicinal Chemistry RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) Phenothiazine: The Parent Molecule
Current Drug Targets Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Radioprotective Gene Therapy
Current Gene Therapy Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Network Propagation Reveals Novel Features Predicting Drug Response of Cancer Cell Lines
Current Bioinformatics Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Preclinical Evaluation of a Monoclonal Antibody (3C6) Specific for Prostate-Specific Membrane Antigen
Current Radiopharmaceuticals DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention
Current Topics in Medicinal Chemistry An Insight into the Role of E2F1 in Breast Cancer Progression, Drug Resistance, and Metastasis
Current Molecular Medicine Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Artificial Virus as Trump-card to Resolve Exigencies in Targeted Gene Delivery
Mini-Reviews in Medicinal Chemistry Aminolevulinic Acid Derivatives and Liposome Delivery as Strategies for Improving 5-Aminolevulinic Acid- Mediated Photodynamic Therapy
Current Medicinal Chemistry